Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment25 Nov 2018
Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms.
Recipharm's proprietary molecule Erdosteine has been officially recognised by the GOLD (Global Initiative for Chronic Obstructive Lung disease) Scientific Committee as one of the commonly used maintenance medications in COPD (Chronic Obstructive Pulmonary Disease).
Erdosteine, which was discovered and developed in Italy by Recipharm’s facility in Paderno Dugnano, has been listed in the 2019 GOLD report. Since its introduction in 2001, the GOLD report has become a leading worldwide reference for all healthcare professionals and health authorities for the effective diagnosis, management and prevention of COPD.
Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms including a capsule, sachet, dispersible tablet and suspension. Recipharm supplies Erdosteine as both API and as finished dose form to its customers.
Pierfrancesco Manzo, Sales & Business Development Director for Erdosteine commented: “This is an important recognition of the scientific value of our molecule and it has been achieved thanks to the outcomes of the recent clinical studies which proved Erdosteine to be effective in the treatment of COPD patients. We are confident that Erdosteine is going to play an increasing role in the treatment of this pathology.”
The recognition in the GOLD report follows extensive research as part of the RESTORE study published in 2017, which saw 467 patients in ten countries undergo 12 months of treatment with positive results that support its clinical effectiveness.
Erdosteine’s pharmacological profile is characterised by unique multifactorial activity: muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant. The chemical synthesis of the API and the manufacture of capsules and dispersible tablets is performed in Recipharm’s Paderno Dugnano facility, located just outside of Milan.
Chemspace and LabNetwork collaborate to extend access to chemical databases
14 Feb 2019
Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.Read more
SGS to conduct its first malaria human challenge trial in Belgium
13 Feb 2019
The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.Read more
Post-EU FMD deadline - 'business as usual'?
12 Feb 2019
Partner connectivity will be an immediate and ongoing challenge beyond the deadline and several pharma companies are likely to break agreements with current suppliers through breach of contract clauses.Read more
BASF opens Application Technology Laboratory for personal care in Nigeria
11 Feb 2019
Local competence in application and formulation technology for sub-Saharan African personal care market.Read more
FDA approves first Nanobody-based medicine for adults with aTTP
10 Feb 2019
Cablivi is the first US approval for Sanofi's new rare blood disorders franchise.Read more
Pharmapack Europe 2019 Award Winners
7 Feb 2019
Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
New series of advanced freeze dryers
6 Feb 2019
The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.Read more
Hitachi Chemical to acquire apceth Biopharma
5 Feb 2019
Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.Read more
FDA approves first generic Advair Diskus
4 Feb 2019
Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation